Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
PARP inhibitors
castration-resistant prostate cancer
genomic biomarkers
precision treatment
Journal
Pharmacogenomics
ISSN: 1744-8042
Titre abrégé: Pharmacogenomics
Pays: England
ID NLM: 100897350
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
7
10
2020
medline:
14
8
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
Precision therapy for a subgroup of genetically defined metastatic castration-resistant prostate cancer patients may become a reality in the near future. DNA damage repair gene mutated prostate cancer might be vulnerable to treatment with PARP inhibitors (PARPi). PARPi clinical trials for prostate cancer investigate both germline and somatic genomic alterations of 43 genes for the applicability as genomic biomarker of PARPi sensitivity. Clinical trials with preliminary results show that
Identifiants
pubmed: 33021139
doi: 10.2217/pgs-2020-0019
doi:
Substances chimiques
Biomarkers, Tumor
0
Genetic Markers
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM